Because a high expression of CD47 on tumour cells might be a new target in treating sarcoma patients, the use of CD47 antibodies has been tested using both in vitro and in vivo models of leiomyosarcoma [45], as well as a xenograft model of human osteosarcoma [46]. This evidence concerns the gene CD47 and leiomyosarcoma.